These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 27013592)

  • 1. Biomarker development in MET-targeted therapy.
    Zhang Y; Du Z; Zhang M
    Oncotarget; 2016 Jun; 7(24):37370-37389. PubMed ID: 27013592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatocyte growth factor/MET in cancer progression and biomarker discovery.
    Matsumoto K; Umitsu M; De Silva DM; Roy A; Bottaro DP
    Cancer Sci; 2017 Mar; 108(3):296-307. PubMed ID: 28064454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The emerging role of MET/HGF inhibitors in oncology.
    Scagliotti GV; Novello S; von Pawel J
    Cancer Treat Rev; 2013 Nov; 39(7):793-801. PubMed ID: 23453860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the hepatocyte growth factor/Met pathway in cancer.
    De Silva DM; Roy A; Kato T; Cecchi F; Lee YH; Matsumoto K; Bottaro DP
    Biochem Soc Trans; 2017 Aug; 45(4):855-870. PubMed ID: 28673936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MET-targeted therapy for gastric cancer: the importance of a biomarker-based strategy.
    Kawakami H; Okamoto I
    Gastric Cancer; 2016 Jul; 19(3):687-95. PubMed ID: 26690587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The scatter factor signaling pathways as therapeutic associated target in cancer treatment.
    Accornero P; Pavone LM; Baratta M
    Curr Med Chem; 2010; 17(25):2699-712. PubMed ID: 20586722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MET receptor in oncology: From biomarker to therapeutic target.
    Malik R; Mambetsariev I; Fricke J; Chawla N; Nam A; Pharaon R; Salgia R
    Adv Cancer Res; 2020; 147():259-301. PubMed ID: 32593403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LY2875358, a neutralizing and internalizing anti-MET bivalent antibody, inhibits HGF-dependent and HGF-independent MET activation and tumor growth.
    Liu L; Zeng W; Wortinger MA; Yan SB; Cornwell P; Peek VL; Stephens JR; Tetreault JW; Xia J; Manro JR; Credille KM; Ballard DW; Brown-Augsburger P; Wacheck V; Chow CK; Huang L; Wang Y; Denning I; Davies J; Tang Y; Vaillancourt P; Lu J
    Clin Cancer Res; 2014 Dec; 20(23):6059-70. PubMed ID: 25231402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HGF/MET pathway aberrations as diagnostic, prognostic, and predictive biomarkers in human cancers.
    Moosavi F; Giovannetti E; Saso L; Firuzi O
    Crit Rev Clin Lab Sci; 2019 Dec; 56(8):533-566. PubMed ID: 31512514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MET as a possible target for non-small-cell lung cancer.
    Sadiq AA; Salgia R
    J Clin Oncol; 2013 Mar; 31(8):1089-96. PubMed ID: 23401458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Developing biomarkers to predict benefit from HGF/MET pathway inhibitors.
    Koeppen H; Rost S; Yauch RL
    J Pathol; 2014 Jan; 232(2):210-8. PubMed ID: 24105670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomic Status of
    Peacock JD; Pridgeon MG; Tovar EA; Essenburg CJ; Bowman M; Madaj Z; Koeman J; Boguslawski EA; Grit J; Dodd RD; Khachaturov V; Cardona DM; Chen M; Kirsch DG; Maina F; Dono R; Winn ME; Graveel CR; Steensma MR
    Cancer Res; 2018 Jul; 78(13):3672-3687. PubMed ID: 29720369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of MET receptor tyrosine kinase in non-small cell lung cancer and clinical development of targeted anti-MET agents.
    Robinson KW; Sandler AB
    Oncologist; 2013; 18(2):115-22. PubMed ID: 23345546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The current state of molecularly targeted drugs targeting HGF/Met.
    Yano S; Nakagawa T
    Jpn J Clin Oncol; 2014 Jan; 44(1):9-12. PubMed ID: 24371262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MET in Lung Cancer: Biomarker Selection Based on Scientific Rationale.
    Salgia R
    Mol Cancer Ther; 2017 Apr; 16(4):555-565. PubMed ID: 28373408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Dysregulation of HGF/c-Met signal pathway and their targeting drugs in lung cancer].
    Li Y; Liu H; Chen J
    Zhongguo Fei Ai Za Zhi; 2014 Aug; 17(8):625-34. PubMed ID: 25130970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer.
    Drusbosky LM; Dawar R; Rodriguez E; Ikpeazu CV
    J Hematol Oncol; 2021 Aug; 14(1):129. PubMed ID: 34425853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the HGF/Met signaling pathway in cancer therapy.
    Cecchi F; Rabe DC; Bottaro DP
    Expert Opin Ther Targets; 2012 Jun; 16(6):553-72. PubMed ID: 22530990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential responses of MET activations to MET kinase inhibitor and neutralizing antibody.
    Kou J; Musich PR; Staal B; Kang L; Qin Y; Yao ZQ; Zhang B; Wu W; Tam A; Huang A; Hao HX; Vande Woude GF; Xie Q
    J Transl Med; 2018 Sep; 16(1):253. PubMed ID: 30208970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HGF/MET-directed therapeutics in gastroesophageal cancer: a review of clinical and biomarker development.
    Hack SP; Bruey JM; Koeppen H
    Oncotarget; 2014 May; 5(10):2866-80. PubMed ID: 24930887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.